Y-mabs and takeda announce exclusive license and distribution agreement for danyelza® (naxitamab-gqgk) and omburtamab in israel

New york and petach tikva, israel, dec. 04, 2020 (globe newswire) -- y-mabs therapeutics, inc. (nasdaq: ymab) (the “company” or “y-mabs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and takeda israel, a wholly owned subsidiary of takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) announced today that they have entered into an exclusive license and distribution agreement for the registration and commercialization in israel of danyelza for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with cns/leptomeningeal metastasis from neuroblastoma. danyelza (naxitamab-gqgk) was approved by the u.s. fda on november 25, 2020. additionally, y-mabs plans to resubmit the amended bla for omburtamab for the treatment of pediatric patients with cns/leptomeningeal metastasis from neuroblastoma to the fda by the end of 2020 or in early 2021.
YMAB Ratings Summary
YMAB Quant Ranking